{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:40:55Z","timestamp":1791283255910,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370894\uff0c82571026"],"award-info":[{"award-number":["82370894\uff0c82571026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-014"],"award-info":[{"award-number":["2022-PUMCH-B-014"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-C-049"],"award-info":[{"award-number":["2025-PUMCH-C-049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Osteoporosis in men is a common but often neglected health problem. We aim to compare the efficacy and safety of denosumab, zoledronic acid and alendronate in men with osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, comparative, open-label study, 390 men with osteoporosis or osteopenia were included. They were randomized to receive the treatment of denosumab, alendronate, or zoledronic acid for 12\u00a0months. The percentage changes in bone mineral density (BMD), trabecular bone score (TBS) and bone turnover biomarkers (BTMs) during the treatment were evaluated. Safety parameters were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The baseline characteristics were well balanced among the three groups. After 12\u00a0months of treatment, denosumab, alendronate and zoledronic acid significantly increased BMD by 4.83\u2009\u00b1\u20090.89%, 4.32\u2009\u00b1\u20090.77%, 5.18\u2009\u00b1\u20090.73% at lumbar spine, by 2.75\u2009\u00b1\u20090.51%, 2.50\u2009\u00b1\u20090.61% and 2.83\u2009\u00b1\u20090.59% at total hip, TBS was significantly increased by 2.44\u2009\u00b1\u20090.52%, 2.00\u2009\u00b1\u20090.64%, 2.29\u2009\u00b1\u20090.55%, respectively, without significant differences among the three groups. Serum levels of BTMs decreased significantly and similarly in all three groups (all P\u2009&amp;lt;\u2009.05 vs. baseline). Denosumab and alendronate group had fewer adverse events than zoledronic acid group. Denosumab had similar efficacy in patients with different gonadal functions. In patients previously receiving bone resorption inhibitors, denosumab continued to increase BMD and TBS, but the increments were reduced by approximately 30% in BMD at lumbar spine compared with treatment-naive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab, alendronate and zoledronic acid significantly and similarly reduced BTMs, increased BMD and TBS in men with osteoporosis, whether the gonadal function of patients was normal or decreased. Previous anti-bone resorption therapy may partially diminish the efficacy of denosumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ageing\/afag121","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:31:39Z","timestamp":1777289499000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis"],"prefix":"10.1093","volume":"55","author":[{"given":"Bingna","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]},{"name":"Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanye","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3462","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-8789","authenticated-orcid":false,"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-3575","authenticated-orcid":false,"given":"Weigang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-4902","authenticated-orcid":false,"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan No. 1, Dongcheng District, Beijing, Beijing, 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026050714031045000_ref1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2026050714031045000_ref2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"2026050714031045000_ref3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","article-title":"Osteoporosis in men","volume":"10","author":"Vilaca","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050714031045000_ref4","doi-asserted-by":"publisher","first-page":"e2121106","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026050714031045000_ref5","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"2026050714031045000_ref6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s001980070064","article-title":"Long-term risk of osteoporotic fracture in Malm\u00f6","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int"},{"key":"2026050714031045000_ref7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/jbmr.4821","article-title":"Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality","volume":"38","author":"Sing","year":"2023","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1359\/JBMR.041133","article-title":"Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures","volume":"20","author":"Jiang","year":"2005","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"2026050714031045000_ref9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/joim.12586","article-title":"Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project","volume":"281","author":"Katsoulis","year":"2017","journal-title":"J Intern Med"},{"key":"2026050714031045000_ref10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40618-025-02753-8","article-title":"Too late, too often: missed opportunities in male bone health: a real-world portrait from a 14-year specialist referral experience","volume":"49","author":"De Vincentis","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"2026050714031045000_ref11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.20945\/2359-3997000000563","article-title":"Male osteoporosis","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"2026050714031045000_ref12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00774-018-0904-5","article-title":"Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures","volume":"37","author":"Jung","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"2026050714031045000_ref13","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-024-07211-4","article-title":"Sex differences and predictors of anti-osteoporosis medication use in the 12 months after hip fracture surgery in adults 65 or older","volume":"35","author":"Kirk","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026050714031045000_ref14","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026050714031045000_ref15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2026050714031045000_ref16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2026050714031045000_ref17","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO), and the international osteoporosis foundation (IOF) under the auspices of WHO collaborating Center for Epidemiology of musculoskeletal health and aging","volume":"34","author":"Shevroja","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026050714031045000_ref18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ecl.2016.09.005","article-title":"Trabecular Bone score: a new DXA-derived measurement for fracture risk assessment","volume":"46","author":"Silva","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026050714031045000_ref19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and androgens in skeletal physiology and pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol Rev"},{"key":"2026050714031045000_ref20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"key":"2026050714031045000_ref21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1020840311573","article-title":"Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer","volume":"21","author":"Smith","year":"2002","journal-title":"Cancer Metastasis Rev"},{"key":"2026050714031045000_ref22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.eprac.2021.12.013","article-title":"Effects of bisphosphonates on Bone of osteoporotic men with different androgen levels: a case-control study","volume":"28","author":"Zhou","year":"2022","journal-title":"Endocr Pract"},{"key":"2026050714031045000_ref23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1210\/clinem\/dgae012","article-title":"Efficacy and safety of denosumab vs zoledronic acid in OI adults: a prospective, open-label, randomized study","volume":"109","author":"Lin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050714031045000_ref24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jbmr.2817","article-title":"Age- and sex-related changes in Bone microarchitecture and estimated strength: a three-year prospective study using HRpQCT","volume":"31","author":"Shanbhogue","year":"2016","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref26","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/jbmr.3456","article-title":"Low muscle strength and mass is associated with the accelerated decline of Bone microarchitecture at the distal radius in older men: the prospective STRAMBO study","volume":"33","author":"Wagner","year":"2018","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref27","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/jbmr.124","article-title":"Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study","volume":"25","author":"Chaitou","year":"2010","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050714031045000_ref29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","article-title":"The clinical effectiveness of denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective Estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis","volume":"112","author":"Moshi","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2026050714031045000_ref30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jcph.2378","article-title":"Five-year outcomes of continuous treatment with zoledronic acid versus denosumab in older men with high fracture risk: risk factor analysis of Bone density improvement and incidence of new fracture","volume":"64","author":"Wu","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"2026050714031045000_ref31","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050714031045000_ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-022-06567-9","article-title":"The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis","volume":"34","author":"Kanis","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026050714031045000_ref33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12020-021-02806-x","article-title":"DXA parameters, trabecular Bone score (TBS) and Bone mineral density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis","volume":"74","author":"Shevroja","year":"2021","journal-title":"Endocrine."},{"key":"2026050714031045000_ref34","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3390\/cancers16111991","article-title":"Metabolic response to androgen deprivation therapy of prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers."},{"key":"2026050714031045000_ref35","doi-asserted-by":"publisher","first-page":"1759720x241234584","DOI":"10.1177\/1759720X241234584","article-title":"The sequential antifracturative treatment: a meta-analysis of randomized clinical trials","volume":"16","author":"Fassio","year":"2024","journal-title":"Therapeutic advances in musculoskeletal disease"},{"key":"2026050714031045000_ref36","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050714031045000_ref37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jbmr\/zjae201","article-title":"The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project","volume":"40","author":"Schini","year":"2025","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research."},{"key":"2026050714031045000_ref38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00198-025-07754-0","article-title":"Complementary effects of trabecular bone score and hip axis length on fracture risk: the Manitoba BMD registry","volume":"37","author":"Leslie","year":"2026","journal-title":"Osteoporos Int"},{"key":"2026050714031045000_ref39","doi-asserted-by":"publisher","first-page":"1628434","DOI":"10.3389\/fendo.2025.1628434","article-title":"Bone turnover markers (\u03b2-CTX, PINP, ALP) in osteoporosis: correlation with bone loss and fracture risk stratification","volume":"16","author":"Wu","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026050714031045000_ref40","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1210\/clinem\/dgaf569","article-title":"Anti-fracture efficacy of 5- or 10- yearly zoledronate in women aged 50-60y: secondary analyses of a randomized trial","volume":"111","author":"Bolland","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/5\/afag121\/68245042\/afag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/5\/afag121\/68245042\/afag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:03:17Z","timestamp":1778176997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afag121\/8672059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afag121","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"afag121"}}